SERF2 Antibody
Description
Fundamental Characteristics of SERF2 Antibody
SERF2 antibodies are immunological reagents specifically developed to recognize and bind to SERF2 protein, the human ortholog of the C. elegans MOAG-4 gene. SERF2 has been identified as a positive regulator of protein aggregates, with research demonstrating that inactivation of MOAG-4 leads to a rescue from proteotoxicity . This discovery has significant implications for human diseases characterized by protein aggregation, including Alzheimer's disease and Parkinson's disease. Furthermore, studies have shown that SERF2 can induce huntingtin aggregation in SK-N-SH neuroblastoma cells, highlighting its potential role in multiple neurodegenerative conditions .
Most commercial SERF2 antibodies are polyclonal in nature, predominantly produced in rabbits. These antibodies are specifically designed to detect endogenous levels of total SERF2 protein across multiple species, with most displaying reactivity against human, mouse, and rat SERF2 . The immunogens used for antibody production typically include synthetic peptides derived from human SERF2 protein sequences or recombinant SERF2 fusion proteins, ensuring high specificity and robust detection capabilities.
The molecular target of these antibodies, SERF2 protein, possesses several unique characteristics. It has a relatively small molecular weight of approximately 7-14 kDa as observed in SDS-PAGE analysis, consists of 59 amino acids, and is rich in specific amino acid residues (glutamic acid, aspartic acid, arginine, and lysine) . SERF2's protein aliases include 4F5rel, Gastric cancer-related protein VRG107, and Protein 4F5-related, while its gene aliases encompass 4F5REL, FAM2C, H4F5REL, HsT17089, and SERF2 .
Research Applications of SERF2 Antibody
SERF2 antibodies have demonstrated utility across multiple research techniques, enabling detailed investigation of SERF2 expression, localization, and function in various experimental systems.
Western Blotting Applications
Western blotting represents one of the most common applications for SERF2 antibodies, facilitating detection and quantification of SERF2 protein in cell and tissue lysates. The recommended dilutions for this application typically range from 1:500 to 1:2000, depending on the specific antibody and experimental conditions . When properly optimized, these antibodies detect bands corresponding to the expected molecular weight of SERF2 (approximately 7-14 kDa). For example, Proteintech reports that their SERF2 antibody (11691-1-AP) shows positive Western blot detection in HepG2 cells at a recommended dilution of 1:500-1:1000 .
Immunohistochemistry and Immunofluorescence
SERF2 antibodies serve as valuable tools for immunohistochemistry (IHC) and immunofluorescence (IF) applications, enabling visualization of SERF2 distribution in tissue sections and cultured cells. For these applications, typical dilutions range from 1:20 to 1:500 .
Proteintech's SERF2 antibody has demonstrated positive IHC detection in human skin cancer tissue and positive IF/ICC detection in A549 and MCF-7 cells . For optimal results in IHC applications, antigen retrieval with TE buffer pH 9.0 or alternatively with citrate buffer pH 6.0 is often recommended. These techniques provide crucial insights into the subcellular localization of SERF2 and its potential co-localization with other proteins or cellular structures.
Immunoprecipitation and ELISA
Beyond imaging applications, SERF2 antibodies are employed in biochemical techniques such as immunoprecipitation (IP) and enzyme-linked immunosorbent assay (ELISA). For IP applications, Proteintech recommends using 0.5-4.0 μg of their SERF2 antibody for 1.0-3.0 mg of total protein lysate, with positive IP detection reported in HepG2 cells . ELISA applications allow for quantitative detection of SERF2 protein, with most manufacturers listing ELISA as a validated application for their SERF2 antibodies .
The following table summarizes recommended dilutions for various applications across different SERF2 antibody products:
| Manufacturer | Product | WB Dilution | IHC Dilution | IF/ICC Dilution | IP Amount |
|---|---|---|---|---|---|
| Proteintech | 11691-1-AP | 1:500-1:1000 | 1:50-1:500 | 1:50-1:500 | 0.5-4.0 μg |
| Abbexa | Not specified | 1:500-1:2000 | Not specified | 1:20-1:200 | Not specified |
| OLS-Bio | 11691-1-AP | Not specified | Not specified | Not specified | Not specified |
SERF2 Antibody in Neurodegenerative Disease Research
SERF2 antibodies have proven instrumental in advancing our understanding of neurodegenerative diseases, particularly those characterized by protein aggregation pathologies.
Role in Studying Amyloid Formation Mechanisms
Research utilizing SERF2 antibodies has revealed that SERF2 promotes amyloid formation through its positively charged N-terminus, which interacts with negatively charged regions in amyloidogenic proteins such as alpha-synuclein and amyloid-beta . Studies have demonstrated that SERF2 drives protein aggregation and toxicity specifically through interactions with negatively charged segments in aggregation-prone proteins .
These findings were established through experiments where the formation of both alpha-synuclein and amyloid-beta thioflavin T (ThT)-positive species was accelerated in the presence of wild-type SERF protein. Equimolar amounts of SERF2 with alpha-synuclein strongly reduced the initial lag phase, and the half-time of conversion was reduced by about 60% . Additionally, both the initial lag phase and midpoint of amyloid growth for amyloid-beta aggregation were reduced by about 30% in the presence of SERF2 .
SERF2 in Alzheimer's Disease Research
SERF2 antibodies have contributed significantly to Alzheimer's disease research, particularly in understanding the structural composition of amyloid deposits. In a mouse model for amyloid-β aggregation (APPPS1-21), brain-specific depletion of Serf2 altered the binding of structure-specific amyloid dyes previously used to distinguish amyloid polymorphisms in the human brain .
Studies utilizing scanning transmission electron microscopy (STEM) revealed that plaques from Alzheimer's model mice with brain-specific Serf2 knockout tended to show more condensed plaques composed of short, thick, and densely packed bundles of fibers with little space in between. In contrast, normal Alzheimer's model mice displayed more loosely packed fibrils . These findings suggest that Serf2 depletion changes the structure of amyloid deposits, potentially offering new insights into amyloid polymorphism and its role in disease progression.
Developmental Implications of SERF2
Research employing SERF2 antibodies has uncovered unexpected developmental roles for this protein. Studies with conditional Serf2 knockout mice revealed that full-body deletion of Serf2 delayed embryonic development, causing premature birth and perinatal lethality . Specifically, these mice exhibited lung maturation defects, leading to respiratory failure shortly after birth .
Interestingly, brain-specific Serf2 knockout mice were viable and showed no major behavioral or cognitive abnormalities, although they did display an approximately 10% reduction in brain weight compared to wild-type mice . This brain weight difference was already present at 1 month of age and remained at least up to 11 months of age, suggesting a role for SERF2 in normal brain development.
Validation and Experimental Controls
Proper validation and controls are essential for ensuring the specificity and reliability of results obtained with SERF2 antibodies. Manufacturers typically validate their antibodies through various methods, including:
-
Western blotting with lysates from cells known to express SERF2 (e.g., HepG2 cells)
-
Immunoprecipitation followed by mass spectrometry
-
Immunostaining of cells and tissues with known SERF2 expression patterns
-
Testing in knockout or knockdown systems to confirm specificity
Researchers should incorporate appropriate positive and negative controls in their experiments to validate the specificity of SERF2 antibody detection. Positive controls might include cell lines with confirmed SERF2 expression, while negative controls could include samples treated with secondary antibody only or samples from SERF2 knockout systems.
Recent Research Advances Using SERF2 Antibody
Recent studies utilizing SERF2 antibodies have provided significant insights into the role of SERF2 in amyloid pathology and neurodegenerative diseases. A landmark study published in 2023 demonstrated that brain-specific deletion of Serf2 in an Alzheimer's disease mouse model resulted in altered binding of structure-specific amyloid dyes, suggesting a change in amyloid deposit structure .
Additionally, research published in 2021 elucidated the molecular mechanism by which SERF2 drives amyloid formation. This study demonstrated that SERF2 binds preferentially to negatively charged amino acids and that this binding and its catalyzing effect on amyloid formation required SERF2's evolutionarily conserved positively charged N-terminal domain . The research showed that neutralizing the charge in the endogenous locus of MOAG-4 (the C. elegans ortholog of SERF2) strongly reduced the aggregation of a reporter substrate, suggesting that neutralizing the charge of a single protein in the cell's proteome is sufficient to alter proteome stability.
Future Directions in SERF2 Antibody Research
The continued development and application of SERF2 antibodies promise to further expand our understanding of SERF2's roles in health and disease. Several emerging areas of research are particularly promising:
The development of new SERF2 antibodies with enhanced properties could facilitate more detailed studies of SERF2 function. These might include monoclonal antibodies targeting specific epitopes, antibodies recognizing post-translationally modified forms of SERF2, or antibodies optimized for advanced imaging techniques such as super-resolution microscopy.
The finding that brain-specific deletion of Serf2 alters amyloid deposit structure without causing major behavioral or cognitive abnormalities suggests potential therapeutic applications. SERF2 antibodies will be crucial for validating SERF2 as a drug target and for screening compounds designed to modulate SERF2 function or its interactions with amyloidogenic proteins.
Furthermore, SERF2 antibodies may facilitate the development of diagnostic tools for neurodegenerative diseases. If SERF2 levels or modifications correlate with disease progression, SERF2 antibodies could be utilized in diagnostic assays to detect these changes in patient samples.
Product Specs
Target Background
- Human orthologs of MOAG-4, SERF2, and SERF1A are ubiquitously expressed, indicating their involvement in a general cellular pathway. PMID: 20723760
Q&A
What is SERF2 and what are its known cellular functions?
SERF2 is a small EDRK-rich factor belonging to the SERF family and serves as the human ortholog of the C. elegans MOAG-4 gene. Research has revealed that SERF2 functions as a positive regulator of protein aggregation, particularly for amyloidogenic proteins . Recent studies have demonstrated its involvement in stress granule assembly and RNA G-quadruplex binding . Additionally, SERF2 plays critical roles in embryonic development, as evidenced by knockout studies in mice showing developmental delays and perinatal lethality in full-body SERF2 knockout animals .
What SERF2 antibodies are commonly used in research, and what epitopes do they recognize?
Research-grade SERF2 antibodies include polyclonal antibodies like the 11691-1-AP that targets full SERF2 protein and others such as PA5-103311 . These antibodies are typically raised against SERF2 fusion proteins, with 11691-1-AP specifically using SERF2 fusion protein Ag2305 as its immunogen . The epitopes recognized vary by antibody, but they generally target regions that allow detection of the small 7 kDa protein (59 amino acids) without cross-reactivity to other SERF family members .
How should SERF2 antibodies be stored and handled to maintain optimal activity?
SERF2 antibodies should be stored at -20°C, where they remain stable for approximately one year after shipment. The storage buffer typically contains PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Aliquoting is generally unnecessary for -20°C storage, though some preparations (20μl sizes) may contain 0.1% BSA . When working with these antibodies, avoid repeated freeze-thaw cycles by preparing working aliquots for routine experimental use.
What are the validated applications for SERF2 antibodies and their recommended dilutions?
SERF2 antibodies have been validated for multiple applications with specific recommended dilutions:
| Application | Dilution |
|---|---|
| Western Blot (WB) | 1:500-1:1000 |
| Immunoprecipitation (IP) | 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | 1:50-1:500 |
| Immunofluorescence (IF)/ICC | 1:50-1:500 |
The antibodies show reactivity with human samples and have cited reactivity with both human and mouse samples . It's recommended to titrate the antibody in each testing system to obtain optimal results, as performance can be sample-dependent.
How can I design experiments to study SERF2 co-localization with stress granule components?
To study SERF2 co-localization with stress granule components, design immunofluorescence experiments using SERF2 antibodies alongside established stress granule markers such as G3BP1, FUS, TIA1, eIF2α, and USP10 . Induce stress granule formation using sodium arsenite (standard treatment), sorbitol, or proteasome inhibitors like MG132 . Include both unstressed and stressed conditions, and analyze co-localization using confocal microscopy and appropriate co-localization statistics. Cell lines like U2OS, BJ fibroblasts, HEK293T, and HeLa Kyoto have been successfully used in such studies .
What controls should I include when using SERF2 antibodies in immunohistochemistry?
For immunohistochemistry with SERF2 antibodies, include both positive and negative controls. For positive controls, use tissues known to express SERF2, such as human skin cancer tissue where positive IHC staining has been documented . For negative controls, include: (1) a primary antibody omission control, (2) an isotype control using rabbit IgG at matching concentration, and (3) when possible, tissue from SERF2 knockout models as a definitive negative control . For antigen retrieval, use TE buffer at pH 9.0, though citrate buffer at pH 6.0 can serve as an alternative .
How does SERF2 influence amyloid formation, and how can this be studied experimentally?
SERF2 acts as a positive regulator of protein aggregation, specifically accelerating the aggregation of amyloidogenic proteins without becoming incorporated into the amyloid fibrils itself . To study this experimentally:
-
Use in vitro aggregation assays with purified amyloidogenic proteins (e.g., amyloid-beta, α-synuclein) in the presence and absence of SERF2
-
Employ thioflavin T fluorescence to monitor aggregation kinetics
-
Utilize conformation-specific dyes like qFTAA and hFTAA (luminescent conjugated oligothiophenes) to distinguish amyloid polymorphisms
-
Complement with electron microscopy to visualize structural differences in the aggregates
-
Create SERF2 knockout models and assess effects on amyloid deposition and structure
How can I study the role of SERF2 in neurodegenerative disease models?
To study SERF2's role in neurodegenerative disease models:
-
Generate brain-specific SERF2 knockout mice (Serf2br−/−) and cross them with disease models (e.g., APPPS1 mice for Alzheimer's disease)
-
Analyze pathological hallmarks using immunohistochemistry with disease-specific antibodies (e.g., 6E10 or W0-2 for Aβ plaques)
-
Employ structure-specific amyloid dyes like qFTAA and hFTAA to characterize amyloid polymorphisms
-
Quantify both extracellular deposits and intracellular accumulation at different ages (1-month, 3-months)
-
Assess cognitive and behavioral outcomes to correlate molecular findings with functional effects
Studies have shown that SERF2 depletion can change the structure of amyloid deposits in the brain, offering potential for polymorphism-based interventions in neurodegenerative diseases .
What is the relationship between SERF2 and stress granule formation?
SERF2 plays a critical role in stress granule assembly. Experimental evidence shows that:
-
SERF2 forms prominent cytoplasmic puncta and co-localizes with stress granule markers (G3BP1, FUS, TIA1, eIF2α, USP10) under various stress conditions
-
SERF2 knockdown results in significantly fewer and smaller stress granules in multiple cell types (U2OS, BJ fibroblasts, HEK293T)
-
CRISPR-Cas9 knockout of SERF2 in HEK293T cells reduces stress granule formation after sodium arsenite treatment
-
Live cell imaging using stress granule markers like EGFP-FUS shows dramatically fewer cytosolic puncti in SERF2 knockdown cells following various stressors
To study this relationship, researchers should use established stress inducers (sodium arsenite, sorbitol, MG132) and measure stress granule formation using immunofluorescence for stress granule markers or live cell imaging with fluorescently tagged proteins like EGFP-FUS.
How can I investigate the RNA G-quadruplex binding properties of SERF2?
To investigate SERF2's RNA G-quadruplex binding properties, researchers can employ several advanced techniques:
-
FOREST (Finding of Recognized Elements in Secondary sTructure) screening approach using diverse RNA pools generated from randomized DNA libraries
-
Compare binding in conditions that promote G-quadruplex formation (KCl buffer) versus conditions that disfavor it (LiCl buffer)
-
Use RNA pools synthesized with 7-deaza guanine (which eliminates G-quadruplex formation) as controls
-
Perform k-mer enrichment analysis (k=6) to identify features of RNAs preferentially associated with SERF2
-
Measure binding affinities to known G-quadruplex forming sequences (e.g., UGGGGU six-repeats, TERRA repeats, G4C2 hexanucleotide repeats)
Research has shown that SERF2 preferentially binds to G-rich sequences that form G-quadruplexes, with binding intensities significantly higher for G-quadruplex sub-libraries compared to other sequences .
What methods can be used to study SERF2 gene regulation?
To study SERF2 gene regulation, researchers can employ these methodologies:
-
Chromatin Immunoprecipitation (ChIP) assays to identify transcription factors binding to the SERF2 promoter, as demonstrated with HSF1
-
Luciferase reporter assays with wild-type and mutated SERF2 promoter constructs to validate regulatory elements
-
Site-directed mutagenesis to disrupt specific binding sites (e.g., HSE elements) in the promoter
-
Transient ChIP assays using transfected promoter constructs to confirm binding of specific transcription factors
-
Real-time RT-PCR to quantify SERF2 expression levels across different conditions and genotypes
Research has shown that heat shock factor 1 (HSF1) binds to and trans-activates the SERF2 promoter, providing insight into how SERF2 expression is regulated during stress responses .
How can I identify potential SERF2 binding partners?
To identify SERF2 binding partners, several approaches can be employed:
-
Virotrap, a virus-based method that has proven successful when traditional methods like co-immunoprecipitation and yeast-two-hybrid screening failed
-
Analyze potential binding partners using computational algorithms to predict:
-
Validate predicted interactions using techniques like:
-
Pull-down assays with purified proteins
-
Proximity ligation assays in cells
-
FRET or BiFC (Bimolecular Fluorescence Complementation) to detect interactions in living cells
-
Research suggests that SERF2 may interact with proteins through charge-based interactions, particularly binding to negatively charged regions of proteins like TRIM26, ATXN3, and NSFL1C .
What are the key considerations when using SERF2 antibodies for Western blotting?
When using SERF2 antibodies for Western blotting, consider these methodological aspects:
-
Sample preparation: SERF2 is a small protein (7 kDa), so use appropriate gel systems (15-20% gels) and transfer conditions optimized for small proteins
-
Positive controls: HepG2 cells have been confirmed to express SERF2 and serve as reliable positive controls
-
Loading controls: Use appropriate loading controls like β-actin as demonstrated in multiple studies
-
Antibody dilution: Use the recommended dilution (1:500-1:1000) and titrate if necessary
-
Detection method: Enhanced chemiluminescence is suitable, but more sensitive methods may be required for low-abundance detection
-
Expected band: Look for a band at approximately 7 kDa (59 amino acids)
When comparing wild-type, heterozygous, and knockout tissues (as in Serf2+/+, Serf2+/−, and Serf2−/− mice), Western blotting can confirm complete absence of the protein in knockout samples .
How can I optimize immunofluorescence protocols for SERF2 detection?
To optimize immunofluorescence protocols for SERF2 detection:
-
Cell fixation: Use 4% paraformaldehyde for 15-20 minutes at room temperature
-
Permeabilization: 0.1-0.5% Triton X-100 for 5-10 minutes
-
Blocking: 5% BSA or normal serum for 1 hour
-
Primary antibody: Apply SERF2 antibody at 1:50-1:500 dilution and incubate overnight at 4°C
-
Validated cell lines: A549 and MCF-7 cells have been confirmed for positive IF/ICC detection
-
Co-staining: When studying stress granules, co-stain with established markers like G3BP1, FUS, or TIA1
-
Counterstaining: Use DAPI for nuclear visualization
-
Controls: Include primary antibody omission controls and, when available, SERF2 knockout cells
For stress granule studies, include both untreated cells and cells treated with stress inducers such as sodium arsenite, sorbitol, or MG132 .
What are possible causes and solutions for inconsistent results with SERF2 knockout models?
When working with SERF2 knockout models, inconsistent results may occur due to several factors:
-
Compensation mechanisms: Check for potential compensatory upregulation of related genes like SERF1, although studies have shown no compensatory upregulation of SERF1 in response to SERF2 knockout
-
Developmental timing: Full-body Serf2 knockout causes developmental delays and perinatal lethality, which can complicate interpretation of results; consider using tissue-specific knockouts instead
-
Background strain variations: Ensure consistent genetic background in all experimental groups
-
Incomplete knockout: Validate knockout efficiency through multiple methods including Western blotting and RT-PCR
-
Age-dependent effects: Phenotypes may manifest differently at various ages; for example, effects on amyloid deposits differ between 1-month and 3-month-old mice
-
Methodology differences: Standardize methods for assessing phenotypes, particularly when using structure-specific amyloid dyes or analyzing stress granule formation
For more reliable results, brain-specific Serf2 knockout mice (Serf2br−/−) provide a viable alternative to full-body knockouts for studying SERF2's role in the brain without the complications of developmental defects .
What are the most promising research directions for SERF2 in neurodegenerative disease models?
The most promising research directions for SERF2 in neurodegenerative disease models include:
-
Investigating how SERF2 influences amyloid polymorphisms and how these structural variations affect disease progression
-
Exploring SERF2 as a potential therapeutic target for modulating protein aggregation in diseases like Alzheimer's and Parkinson's
-
Understanding the interaction between SERF2 and RNA G-quadruplexes in the context of neurodegenerative diseases with RNA metabolism defects
-
Determining whether SERF2's role in stress granule assembly connects to pathological stress granule formation in neurodegenerative diseases
-
Developing small molecule inhibitors of SERF2-amyloid interactions as potential disease-modifying agents
